Hu et al. confirmed that targeting PRMT5 in cancer patients with inhibitors hindered lung cancer progression, but conversely augmented PD-L1 expression that inhibited the cytotoxicity of CD8+ T cells resulting in immune resistance [76]. The gene discussed is PRMT5; the disease is lung carcinoma.